Pages that link to "Q73626773"
Jump to navigation
Jump to search
The following pages link to Ian Catlett (Q73626773):
Displaying 10 items.
- Recruitment of CD40 and tumor necrosis factor receptor-associated factors 2 and 3 to membrane microdomains during CD40 signaling (Q22253441) (← links)
- Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants (Q33653945) (← links)
- Suppressor of cytokine signaling 1 is required for the differentiation of CD4+ T cells. (Q46697159) (← links)
- Signaling through MHC class II molecules blocks CD95-induced apoptosis. (Q54010517) (← links)
- Cutting edge: a novel mechanism for rescue of B cells from CD95/Fas-mediated apoptosis (Q78145094) (← links)
- Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS-986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo-controlled trial in healthy participants (Q90557108) (← links)
- Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 Antibody (BMS-936559) (Q91479191) (← links)
- Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain (Q92152979) (← links)
- Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK) (Q92505400) (← links)
- 2018 White Paper on Recent Issues in Bioanalysis: focus on flow cytometry, gene therapy, cut points and key clarifications on BAV (Part 3 - LBA/cell-based assays: immunogenicity, biomarkers and PK assays) (Q93388051) (← links)